← Back to Screener
Bausch + Lomb Corporation (BLCO)
Price$15.39
Value ScoreB
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-8.44%
Price vs S&P 500 (4W)-9.02%
VGM Score52.88
Market Capitalization$5.58B
All Metrics
P/CF (Annual)19.72x
Book Value / Share (Quarterly)$17.90
P/TBV (Annual)1.91x
Revenue Growth (3Y)10.62%
Cash Flow / Share (Quarterly)$0.00
Price vs S&P 500 (YTD)-19.31%
Gross Margin (TTM)60.62%
Net Profit Margin (TTM)-4.21%
EPS (TTM)$-0.62
10-Day Avg Trading Volume0.40M
EPS Excl Extra (TTM)$-0.62
Revenue Growth (5Y)8.38%
EPS (Annual)$-1.02
ROI (Annual)-3.12%
Gross Margin (Annual)59.81%
Net Profit Margin (5Y Avg)-2.99%
Cash / Share (Quarterly)$0.75
Revenue Growth QoQ (YoY)9.41%
ROA (Last FY)-2.57%
Revenue Growth TTM (YoY)7.85%
EBITD / Share (TTM)$1.33
ROE (5Y Avg)-2.45%
Operating Margin (TTM)4.26%
Cash Flow / Share (Annual)$-0.19
P/B Ratio0.87x
P/B Ratio (Quarterly)0.89x
Net Income / Employee (Annual)$-27,700
EV / Revenue (TTM)1.99x
Net Interest Coverage (TTM)0.25x
ROA (TTM)-1.58%
EV / EBITDA (TTM)22.09x
EPS Incl Extra (Annual)$-1.02
Current Ratio (Annual)1.55x
Quick Ratio (Quarterly)0.76x
3-Month Avg Trading Volume0.44M
52-Week Price Return33.53%
EV / Free Cash Flow (Annual)34.57x
Revenue / Employee (TTM)$400,600
Tangible BV / Share (Quarterly)$8.85
P/S Ratio (Annual)1.09x
Asset Turnover (Annual)0.36x
52-Week High$18.91
Operating Margin (5Y Avg)4.57%
EPS Excl Extra (Annual)$-1.02
CapEx CAGR (5Y)6.65%
26-Week Price Return7.49%
Quick Ratio (Annual)0.84x
13-Week Price Return-15.36%
Total Debt / Equity (Annual)0.79x
Current Ratio (Quarterly)1.53x
Enterprise Value$10.38B
Revenue / Share Growth (5Y)8.14%
Asset Turnover (TTM)0.38x
Revenue / Employee (Annual)$392,400
Inventory Turnover (Annual)2.04x
Pretax Margin (Annual)-6.21%
Cash / Share (Annual)$1.08
3-Month Return Std Dev30.84%
Gross Margin (5Y Avg)60.37%
Net Income / Employee (TTM)$-16,800
EBITDA CAGR (5Y)-8.94%
EBITDA Interim CAGR (5Y)1.11%
ROE (Last FY)-5.58%
Net Interest Coverage (Annual)0.52x
EPS Basic Excl Extra (Annual)$-1.02
P/FCF (TTM)45.36x
Receivables Turnover (TTM)4.93x
EV / Free Cash Flow (TTM)10381.79x
Total Debt / Equity (Quarterly)0.79x
EPS Incl Extra (TTM)$-0.62
Receivables Turnover (Annual)4.54x
ROI (TTM)-1.91%
P/S Ratio (TTM)1.07x
Pretax Margin (5Y Avg)-0.94%
Revenue / Share (Annual)$14.42
Tangible BV / Share (Annual)$8.94
Forward P/E19.19x
Price vs S&P 500 (52W)5.33%
Year-to-Date Return-8.37%
5-Day Price Return-1.70%
EPS Normalized (Annual)$-1.02
ROA (5Y Avg)-1.02%
Net Profit Margin (Annual)-7.06%
Month-to-Date Return-1.57%
Cash Flow / Share (TTM)$0.46
EBITD / Share (Annual)$1.03
Operating Margin (Annual)2.10%
LT Debt / Equity (Annual)0.78x
P/CF (TTM)16.41x
ROI (5Y Avg)-1.24%
LT Debt / Equity (Quarterly)0.79x
EPS Basic Excl Extra (TTM)$-0.62
P/TBV (Quarterly)1.80x
P/B Ratio (Annual)0.94x
Inventory Turnover (TTM)2.04x
Pretax Margin (TTM)-3.86%
Book Value / Share (Annual)$18.20
Price vs S&P 500 (13W)-25.11%
Beta0.57x
P/FCF (Annual)32.82x
Revenue / Share (TTM)$14.66
ROE (TTM)-3.41%
52-Week Low$11.22
vGradeB
gGradeC
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 260.08est. 0.06
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
3.63
3.58
3.58
3.58
Industry Peers — Ophthalmic Goods(8)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BLCOBausch + Lomb Corporation | B | C | C | $15.39 |
| ALCAlcon Inc. Ordinary Shares | C | C | C | $65.70 |
| COOThe Cooper Companies, Inc. Common Stock | C | C | D | $60.19 |
| WRBYWarby Parker Inc. | D | B | C | $24.38 |
| STAAStaar Surgical Co | D | C | B | $29.55 |
| EYENational Vision Holdings, Inc. Common Stock | A | D | D | $16.08 |
| RXSTRxSight, Inc. Common Stock | B | C | F | $5.24 |
| LUCYInnovative Eyewear, Inc. Common Stock | B | A | D | $1.00 |
| LUCYWInnovative Eyewear, Inc. Series A Warrants 8/16/27 | — | — | D | $0.05 |
About
Bausch & Lomb is one of the largest US vision care companies, operating three segments: vision care (contact lenses with ~10% market share, plus brands like Biotrue and Lumify), surgical devices for ophthalmic procedures, and ophthalmic pharmaceuticals. The company was spun off from Bausch Health in 2022 and maintains the industry's largest portfolio of eye care prescriptions, with over 100 products. This diversified portfolio across consumer, surgical, and pharmaceutical markets provides exposure to multiple customer segments within ophthalmology.